中东和非洲医药商业洞察

Middle East & AfricaPharmaceutical Business Insights Thirty-Seventh Edition Report Release Date: Sep 2025Analytical Timeframe: MAT Jun 2025 © 2025. All rights reserved. IQVIA®is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. Disclaimer IQVIA is not an “authorised person” for the purposes of the Financial Services and Markets Act 2000 (“FSMA”) and does not provideinvestment advice or carry on any other regulated activity under Part II of the FSMA 2000 (Regulated Activities) Order 2001 The forecasts, projections, and related information contained herein are made and provided subject to the assumptions, methodologies,caveats, and variables described in this report and are based on third party sources and data reasonably believed to be reliable. Nowarranty is made as to the completeness or accuracy of such third party sources or data This report, in part or in whole, is not intended to constitute investment advice, and is not a recommendation to purchase ornot purchase,an endorsement of, or an opinion as to the value of, any security or any investment instrument of any entity As with any attempt to estimate future events, the forecasts, projections, conclusions, and other information included hereinare subject tocertain risks and uncertainties, and are not to be considered guarantees of any particular outcome This report shall not be published, nor shall any public references to IQVIA be made regarding these services or this report,without IQVIA’prior written approval. When so provided, this report and the information herein must always be provided and used in its entirety, includingthis complete Disclaimer page This report is subject to the IQVIA General Terms and Conditions. Agenda +Newsletter report summary+Regional summary and analysis+Spotlight on new offering+Appendix Business insights snapshot MAT Q2 2025: Many countries have witnessedhigh growth in 2025 •Saudi Arabia leads the MEA region at$14.6Binvalue, expanded at24.4% PPGin value terms•UAE follows as the 2ndlargest, with$4.87 Bin valuehas seen a growth of10.8% PPG and 16.3%CAGR2 Among the key countries, KSA saw growth of 24.4% and continues to lead,accounting for 37.6% of sales in MEA Region South Africa1 United Arab Emirates (UAE) •UAE grew by 10.8% PPG (3rdfastest growing country inMEA region**)accounting for $4.87 B sales•Top 10 TAsaccount for49.1%of total sales, whereinNewerGen Type II Antidiabetics TA is growing at 15.9% PPG•Top 10 corporationsaccount for47.3% sharein sales withPfizerbeing the fastest growing at20.5% PPG; mainly drivenby top brands likeNurtec(49.5%), Prevnar (117.8%), andEliquis (17.1%) on PPG •South Africa has grown by 1.77% PPG accounting for $3.5B saleswith theretail channel accounting for 84.3% oftotal sales•Cough & Cold Preparations TA continues to be Top TA at-1.4% PPG and 6.2% share•Top 10 corporationsaccount for51.5%share in sales.Adcock Ingram, a local firm, is leading with9.9%share andNovo Nordiskbeing the fastest growing at28.2%PPG Saudi Arabia (KSA) Egypt (EGY)* •Egypt volume sales has increased by 1.13% PPGdriven bygrowth fromRetail channel (2.69% PPG) accounting for 82%of country’s Units sales•Systemic Antibacterialsis the top TA in Egypt with10.4%Units share whileDermatological Anti-Infectives (10.9%PPG) is the fastest growingamongst the top 10 TAs•Top 10 corporations account for 41.9% sharein volumesales,Pharco is leadingthe sales with7.8% share and Apexisthe fastest growing corporation among top 10 corps(36%PPG) •Saudi Arabia has grown by 24.41% PPG, making it the fastestgrowing country in MEA, with sales valued at $14.6 B•Hospital channel (Hospitals + LPO) grew by 33.19% PPGandaccounting for51.2% of total sales•Top 10 corporationsaccount for43.8%share in sales. HikmaPharmais leading with6. 8%shareand40.5%PPG•Hikma Pharmais the fastest growing Local/Regcorpmainly drivenby top brands likeMegamox(46.4%),Remsima(133.3%),Omeral(25%) andTorvast(20.5%) on PPG Algeria business in MEA is growing at 6.5% PPG mainly driven bylocal/regional players with 14.53% PPG Algeria (ALG) Fr. West Africa (FWA) FWA •FWA retail channel has grown by 7.64% PPG accountingfor $1.9 B sales inMAT Q2 2025•Local/Regional playersgrew by9.95% PPGwhile accountingfor51.96% of total sales•Amongst the top 10 corporations,Sanoficontinues to be thetopselling corporation with5.8% sharewhileGenericHealthcare is the fastest growing top corporation at 21.7%PPGamongst the top 10 corporations.•Generic Healthcaregrowth is driven by top products likeAmloperin(25.1% PPG),Ramithiazide(9.8% PPG) andArtrim(-2.1% PPG) •Algeria retail channel sales increased by 6.5% PPGaccountingfor$2.7 Bsales in MAT Q2 2025 period•Top TAs for AlgeriaareAntihypertensives(8.0% PPG) andInsulin & Analogs(0.01% PPG).Allergy is the fastest growingTA at 10.2% PPG amongst the top 10 TAs (excl.NonTherapeutics)•MS Pharma is the top corporationin Algeria with7.2% of salesshareandBiocareBiotech SPis fast